First Regular Session | 72nd General Assembly
Colorado General AssemblyThis memorandum provides a brief overview of the timeline of events related to the recommended closure of the Grand Junction Regional Center (GJRC) campus.
Final Report to the Colorado General Assembly by the Legislative Oversight Committee Concerning the Treatment of Persons with Mental Health Disorders in the Criminal and Juvenile Justice Systems.
According to the Colorado Department of Corrections (DOC), between 2012 to 2017, the number of inmates who had moderate to severe mental health needs increased by 7 percent. Additionally, a steep increase in court-ordered competency evaluations and restorative treatments has caused a shortage...
The Opioid and Other Substance Use Disorders Study Committee was created pursuant to Article 22.3 of Title 10, Colorado Revised Statutes. The purpose of this committee is to study issues relating to opioid and substance use disorders in Colorado and examine potential solutions concerning...
During the 2018 session, the General Assembly considered bills related to suicide prevention, requests to study public health effects, changes to certificates and databases overseen by the Department of Public Health and Environment (CDPHE), nad other public health-related legislation.
Final Report to the Colorado General Assembly by the Opioid and Other Substance Use Disorders Interim Study Committee.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Committee Study Committee at its August 1, 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Committee at its August 1, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 22, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 22, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 1, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 22, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at is August 22, 2017, meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its August 22, 2017, meeting.